Evidence map›Paper›PMID 36241847›Full record

ArticleScientific reports2022

Design and function of targeted endocannabinoid nanoparticles.

N Barrie, N Manolios, J Stuart, T Chew, J Arnold, R Sadsad, L De Campo, R B Knott, J White, D Booth and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

N Barrie *Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, 2006, Australia.
N Manolios *Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, 2006, Australia. nicholas.manolios@sydney.edu.au.
J StuartDiscipline of Pharmacology, The University of Sydney, School of Psychology, Sydney, Australia.
T ChewSydney Informatics Hub, Core Research Facilities, The University of Sydney, Sydney, 2006, Australia.
J ArnoldDiscipline of Pharmacology, The University of Sydney, School of Psychology, Sydney, Australia.
R SadsadSydney Informatics Hub, Core Research Facilities, The University of Sydney, Sydney, 2006, Australia.
L De CampoSmall-Angle Neutron Scattering (SANS) Facility, Australian Nuclear Science and Technology Organisation (ANSTO), Lucas Heights, Sydney, NSW, 2234, Australia.
R B KnottSmall-Angle Neutron Scattering (SANS) Facility, Australian Nuclear Science and Technology Organisation (ANSTO), Lucas Heights, Sydney, NSW, 2234, Australia.
J WhiteMaterials Ccharacterization and Modelling, Commonwealth Scientific and Industrial Research Organisation (CSIRO), Manufacturing, Clayton, VIC, 3169, Australia.
D BoothDepartment of Rheumatology, Westmead Hospital, Westmead, Sydney, NSW, 2145, Australia.
M AliDepartment of Rheumatology, Westmead Hospital, Westmead, Sydney, NSW, 2145, Australia.
M J MoghaddamCSIRO, Manufacturing Flagship, North Ryde, Sydney, NSW, 2113, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nanoparticles and nano-delivery systems are constantly being refined and developed for biomedical applications such as imaging, gene therapy, and targeted delivery of drugs. Nanoparticles deliver beneficial effects by both release of their cargo and by liberation of their constitutive structural components. The N-acylethanolamines linoleoyl ethanolamide (LEA) and oleoyl ethanolamide (OEA) both exhibit endocannabinoid-like activity. Here, we report on their ability to form nanoparticles that when conjugated with tissue-specific molecules, are capable of localizing to specific areas of the body and reducing inflammation. The facilitation of pharmacological effects by endocannabinoids at targeted sites provides a novel biocompatible drug delivery system and a therapeutic approach to the treatment, patient management and quality of life, in conditions such as arthritis, epilepsy, and cancer.

Indexed as

EndocannabinoidsNanoparticlesHumansPharmaceutical PreparationsQuality of LifeEndocannabinoidsPharmaceutical Preparations

Identifiers

PMID36241847
PMCPMC9568518

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.